Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04663880
Other study ID # ALY-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 30, 2016
Est. completion date February 15, 2017

Study information

Verified date December 2020
Source Alyatec
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double blind, cross-over study designed to determine the concentration of airborne house dust mite allergen inducing bronchial response in asthmatic subjects allergic to mite, during allergen exposures in the Alyatec environmental exposure chamber (EEC). The study was also designed to validate the specificity of the asthmatic reaction induced by exposure to airborne house dust mite allergen in Alyatec EEC.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date February 15, 2017
Est. primary completion date January 23, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: - Subjects having signed the informed consent - Subjects affiliated to a social security scheme - Positive metacholine test - FEV1 value > 70% of theoretical FEV1 value - Asthma Control Test (ACT) = 20/25 in 4 weeks prior to EEC exposure Group A: - Mild allergic asthma to HDM (GINA 1 or 2) with associated rhinitis and/or conjunctivitis. - Positive skin prick-test to Dpt and Df (wheal diameter >5 mm compared to the negative control) - Specific immunoglobulin E (IgE) for Dpt and Df > 0.7 kU/L Group B: - Mild allergic asthma (GINA 1 or 2) not sensitized to HDM with associated rhinitis and/or conjunctivitis. - Negative skin prick-test and specific IgE for Dpt and Df. - Positive skin prick-test and specific IgE for another allergen. Exclusion Criteria: - Uncontrolled asthma - Asthma Control Test (ACT) < 20/25 in 4 weeks prior to EEC exposure - Use of oral corticosteroids in the 4 weeks preceding inclusion in the study - Use of biotherapy in the 4 months preceding inclusion in the study - Existence of a severe obstructive syndrome with FEV1 <70% of the theoretical value - Obstruction triggered by spirometric evaluations - Hospitalization for asthma or exacerbation in the last 4 weeks - History of Acute Severe Asthma requiring hospitalization in intensive care or intubation - Desensitization to dust mite allergens in the last 5 years - Sensitization to allergens in the indoor environment (cat allergens or molds) with obvious exposure to these allergens - Active tobacco: plus 10 cigarettes / day and tobacco history of +10 PA - Uncontrolled systemic arterial hypertension - Recent myocardial infarction (<3 months) - Recent stroke (<3 months) - Known arterial aneurysm - Epilepsy under treatment - Progressive tumor pathology - Chronic renal pathology - Hypersensitivity to one of the excipients used - Subjects who participated in another clinical study in the three months prior to inclusion

Study Design


Intervention

Other:
Exposure to placebo in EEC
Patients are exposed to placebo (saline solution) in the EEC for 4h maximum
Exposure to three concentrations of HDM allergen in EEC
Patients are exposed to different concentrations of airborne HDM allergen (Der p1) in the EEC for 4h maximum
Exposure to a single concentration of HDM allergen in EEC
Patients are exposed to a single concentration of airborne HDM allergen (Der p1) in the EEC for 4h maximum

Locations

Country Name City State
France Alyatec Strasbourg Grand Est

Sponsors (1)

Lead Sponsor Collaborator
Alyatec

Country where clinical trial is conducted

France, 

References & Publications (1)

Khayath N, Doyen V, Gherasim A, Radu C, Choual I, Beck N, Jacob A, Schoettel F, Vecellio L, Domis N, de Blay F. Validation of Strasbourg environmental exposure chamber (EEC) ALYATEC(®) in mite allergic subjects with asthma. J Asthma. 2020 Feb;57(2):140-14 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the concentration of HDM allergen (in ng/m3 of Der p1) necessary to induce a bronchial response in at least 60% of asthmatic subjects allergic to HDM The bronchial response is evaluated by measuring FEV1 value during EEC exposure.
Early asthmatic response (EAR) occurs when a 20% drop in FEV1 is detected during the exposure compared to the pre-exposure FEV1.
Late bronchial response (LAR) occurs when a 15% drop in FEV1 or 20% drop in peak flow is detected 1 to 6h after the EAR.
10 hours: 4 hours of exposure in the EEC then 6 hours post-exposure.
Secondary Evaluate the safety of allergenic exposure in EEC Safety is assessed with clinical evaluations performed during the 4h of exposure in the EEC 28 hours: 4 hours of exposure in EEC then 24 hours post-exposure
Secondary Evaluate the metrology of the EEC The metrology is assessed with the measure of allergen concentration and particules diameter thanks to sensors in the chamber. 4 hours of exposure in EEC
Secondary Evaluate the specificity of the bronchial response The specificity of the bronchial response is assessed with the HDM exposure in the EEC of asthmatic subjects non allergic to HDM. 4 hours of exposure in EEC
Secondary Evaluate the effect of the exposure on rhinitis symptoms The effect of the exposure on the rhinitis response is assessed with Total Nasal Symptom Score (TNSS).
The TNSS was obtained from the sum of all four individual symptom scores, with a total possible score ranging from 0 (no symptoms) to 12 (maximum symptom intensity).
28 hours: 4 hours of exposure in EEC then 24 hours post-exposure
Secondary Evaluate the effect of the exposure on conjunctivitis symptoms The effect of the exposure on the conjunctivitis response is assessed with Total Ocular Symptom Score (TOSS).
The TOSS was obtained from the sum of all four individual symptom scores, with a total possible score ranging from 0 (no symptoms) to 12 (maximum symptom intensity).
28 hours: 4 hours of exposure in EEC then 24 hours post-exposure
See also
  Status Clinical Trial Phase
Terminated NCT02032056 - Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period N/A
Completed NCT01842711 - Cumulative Irritation Patch Test N/A
Completed NCT01633840 - New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges N/A
Completed NCT00554983 - Efficacy and Safety From a Recombinant Folding Variant of Bet v 1 Phase 3
Completed NCT00997971 - Growth, Tolerance in Healthy Infants Fed a Partially Hydrolyzed Rice Protein Phase 3
Completed NCT00331929 - Respiratory Health Study of Children in Kiryat Tivon N/A
Completed NCT00232518 - Randomised Controlled Clinical Trials of the Effect of Therapeutic Hookworm Infection in Allergic Rhinoconjunctivitis N/A
Completed NCT00220753 - Air Cleaners for Children and Adolescents With Asthma and Dog Allergy N/A
Completed NCT04126096 - Negative Predictive Value and NIC of Beta-Lactam Antibiotics. N/A
Completed NCT04046731 - Neuromuscular Blocking Agents Utilized During Perioperative Hypersensitivity Evaluation N/A
Completed NCT04004351 - Treatment Modalities in Children and Adolescents Suffering From HDM-induced Allergic Rhinitis and/or Asthma
Not yet recruiting NCT05997784 - Study of Indoor Air Pollutants and Their Impact in Childhood Health and Wellbeing
Completed NCT04418999 - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus Early Phase 1
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02127801 - Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants Phase 1
Enrolling by invitation NCT05011071 - The Alberta BLOOM Premature Child Study
Not yet recruiting NCT06330974 - Allergy, Asthma, and Atopic Eczema in Finland
Completed NCT02306473 - The Leaky Lung Test Early Phase 1
Terminated NCT02601690 - Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America
Completed NCT02596321 - A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma Phase 3

External Links